Dahl ML - Search Results

1

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L. Carrillo JA, et al. Among authors: dahl ml. Ther Drug Monit. 2000 Aug;22(4):409-17. doi: 10.1097/00007691-200008000-00008. Ther Drug Monit. 2000. PMID: 10942180

2

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.

Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Llerena A, et al. Among authors: dahl ml. Ther Drug Monit. 1992 Jun;14(3):261-4. doi: 10.1097/00007691-199206000-00014. Ther Drug Monit. 1992. PMID: 1412613

3

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.

Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Llerena A, et al. Among authors: dahl ml. Ther Drug Monit. 1992 Apr;14(2):92-7. doi: 10.1097/00007691-199204000-00003. Ther Drug Monit. 1992. PMID: 1585408

4

Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline.

Dahl ML, Nordin C, Bertilsson L. Dahl ML, et al. Ther Drug Monit. 1991 May;13(3):189-94. doi: 10.1097/00007691-199105000-00001. Ther Drug Monit. 1991. PMID: 1926270

5

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindström L, Rodriguez de la Rubia I, Ramos S, Benitez J. Bertilsson L, et al. Among authors: dahl ml. Br J Clin Pharmacol. 1994 Nov;38(5):471-3. doi: 10.1111/j.1365-2125.1994.tb04385.x. Br J Clin Pharmacol. 1994. PMID: 7893591 Free PMC article. Clinical Trial.

6

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.

Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodríguez I, Bertilsson L. Carrillo JA, et al. Among authors: dahl ml. Clin Pharmacol Ther. 1996 Aug;60(2):183-90. doi: 10.1016/S0009-9236(96)90134-4. Clin Pharmacol Ther. 1996. PMID: 8823236

7

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.

Dahl ML, Tybring G, Elwin CE, Alm C, Andreasson K, Gyllenpalm M, Bertilsson L. Dahl ML, et al. Clin Pharmacol Ther. 1994 Aug;56(2):176-83. doi: 10.1038/clpt.1994.121. Clin Pharmacol Ther. 1994. PMID: 8062494

8

Genetically variable metabolism of antidepressants and neuroleptic drugs in man.

Dahl ML, Bertilsson L. Dahl ML, et al. Pharmacogenetics. 1993 Apr;3(2):61-70. doi: 10.1097/00008571-199304000-00001. Pharmacogenetics. 1993. PMID: 8100166 Review. No abstract available.

9

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Dalén P, Dahl M, Andersson K, Bertilsson L. Dalén P, et al. Br J Clin Pharmacol. 2000 Feb;49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x. Br J Clin Pharmacol. 2000. PMID: 10671914 Free PMC article. Clinical Trial.

10

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.

Dahl ML, Ekqvist B, Widén J, Bertilsson L. Dahl ML, et al. Acta Psychiatr Scand. 1991 Jul;84(1):99-102. doi: 10.1111/j.1600-0447.1991.tb01428.x. Acta Psychiatr Scand. 1991. PMID: 1927573

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters